SCIENTIFIC PROGRAMME
SESSION I
BIOLOGY OF B-CELL
PRECURSOR ALL
SESSION II
BIOLOGY OF T-CELL ALL
SESSION III
MINIMAL RESIDUAL
DISEASE MONITORING
SESSION IV
INDIVIDUALIZED
MANAGEMENT OF ALL
SESSION V
NEW ADVANCES IN ALL
SESSION VI
CAR T-CELLS &
ALLOGENEIC HSCT
SESSION VII
FRONTLINE
INCORPORATION OF
BITES AND ADCS
SESSION VIII
T-CELL ALL AND
LYMPHOBLASTIC
LYMPHOMA
SESSION IX
PH AND PH-LIKE ALL
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES
CLINICAL AND BIOLOGICAL ASPECTS OF PATIENTS SUFFERING FROM ACUTE
LYMPHOBLASTIC LEUKEMIA AND SARS COV 2 INFECTION– DATA PROVIDED FROM
THE ONLY HEMATOLOGY COVID 19 DEPARTMENT IN ROMANIA
Daniela Georgescu1, Andreescu Ana-Maria2, Nicoleta Ilie2, Mihaela Andreescu1 and Viola Maria Popov3
(1) Colentina Clinical Hospital, Bucharest, Romania, (2) Titu Maiorescu University, Bucharest, Romania,
(3) Colentina Hospital Bucharest, Bucharest, Romania
Background: Patients with Acute Lymphoblastic Leukemia (ALL) and SARS COV 2 infection
have a poor prognosis.
Aims: We analyzed the impact of SARS COV 2 infection in patients hospitalized with ALL to
highlight the clinical outcome.
Methods: For analysis we have collected the patients’ medical records: type of diagnosis,
clinical characteristics, laboratory parameters, chest CT imaging, treatment approach, clinical
outcomes.
Results:
The 5 patients, with ages between 28 - 84 years old, diagnosed with ALL, were treated for a
median period of 9,5 days (4-15 days) in our Hematology Department for COVID -19 infection.
4 patients were admitted to the Intensive Care Unit for severe respiratory failure and died.
Only patient was discharged after 4 days of treatment.
When admitted the patients have: cough, fever, dyspnoea, anemia, severe trombocytopenia,
diseminated intravascular coagulopathy and important biological inflammatory syndrom. 4
patients were in aplasia, only one patient had a significant leukocytosis due to ALL progression
(WBC 433.880/mmc).
After examining the patients’ pulmonary CTs, we noticed severe changes in the lungs, specific
to the COVID pneumonia, with damages up to 90 % from pulmonary surface.
Conclusions:
Patients suffering from ALL have weaker immune systems, causing a poor outcome of SARS
COV 2 infection.
POSTER 32